{"eventGroups":[{"deathsNumAffected":1,"deathsNumAtRisk":3,"description":"The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT.\n\nIpilimumab: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"title":"Ipilimumab After Stem Cell Transplantation"}],"frequencyThreshold":"5","timeFrame":"up to a year"}